The Kruppel-like factor (KLF) family of proteins, also known as SP1-like, is made up of a set of transcription factors that are present in a wide range of organisms, in which they fulfill a range of cell differentiation and proliferation functions ([@bib3]; [@bib11]; [@bib26]; [@bib6]). KLFs have Cys2/His2 zinc-finger domains that preferentially bind to GC-rich target sequences, where they can function as activators or repressors in a cell type- and promoter-dependent manner ([@bib3]; [@bib11]; [@bib26]; [@bib6]). KLFs are also emerging as potential tumor suppressor genes owing to their roles in the inhibition of proliferation, migration and angiogenesis, and in the induction of apoptosis, senescence and adhesion ([@bib3]; [@bib11]; [@bib26]; [@bib6]). One member of the family, KLF2, is particularly interesting. Although it is not known to undergo genetic disruption in human tumors, KLF2 expression is diminished in many malignancies, such as prostate ([@bib8]) and ovarian ([@bib21]) cancer. From a functional standpoint, KLF2 possesses tumor-suppressor features such as induction of cell quiescence ([@bib5]), enhancement of DNA-damage-associated apoptosis ([@bib21]), inhibition of leukemia cell proliferation ([@bib22]), anti-angiogenesis properties ([@bib2]), and the suppression of cell growth mediated by KRAS ([@bib9]) and epidermal growth factor receptor ([@bib12]). Thus, we wondered about the molecular basis of the loss-of-function defects of KLF2 in human tumorigenesis and so set out to study the possible role of oncogenic repressive mechanisms.

One of the most important systems for maintaining the heritable repression of genes is that of the Polycomb group proteins ([@bib16]; [@bib14]). These Polycomb group proteins are often de-regulated in human cancer ([@bib15]; [@bib19]). The Enhancer of Zeste Homolog 2 (EZH2) is a component of the Polycomb repressive complex 2, which also includes SUZ12 and EED, and represses gene transcription by trimethylation of Lys27 of histone H3 (H3K27) ([@bib17]). EZH2 has the hallmarks of an oncogene, particularly in prostate and breast cancer, where elevated levels are found in the more advanced forms of the disease ([@bib20]; [@bib4]; [@bib13]). Recently, EZH2 gain-of-function mutations have also been found in lymphomas ([@bib23]). Thus, one way by which EZH2 could promote transformation is by repressing tumor suppressor genes, exploiting its methyltransferase activity for lysine 27 of histone H3 (H3K27) ([@bib17]). In this scenario, several genes with a growth-inhibitory function have recently been found to be targeted by EZH2 in cancer cells ([@bib7]; [@bib1]; [@bib24], [@bib25]; [@bib10]). Thus, we examined whether KLF2 could also be a key tumor suppressor gene targeted for repression by EZH2 in human tumorigenesis.

To assess the putative role of EZH2 in KLF2 repression, we first transiently depleted the expression of EZH2 by RNA interference (RNAi) in MDA-MB-231 and MCF-7 (breast), PC3 and LNCaP (prostate), and U2OS (osteosarcoma) cancer cell lines ([Figures 1a and b](#fig1){ref-type="fig"}). All cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA) and were cultured in Dulbecco\'s modied Eagle\'s medium supplemented with 10% fetal bovine serum. The *in vitro* transient transfection of short interfering RNAs (Qiagen, Valencia, CA, USA) was performed using Oligofectamine (Invitrogen, Carlsbad, CA, USA). We observed that the loss of EZH2 was associated with upregulation of KLF2 at mRNA ([Figure 1a](#fig1){ref-type="fig"}) and protein ([Figure 1b](#fig1){ref-type="fig"}) levels in all the five described cancer cell lines. Upon EZH2 knockdown at 72 h, we also observed a defect on cell viability determined by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay and an increase in G1/decrease in S-phase assessed by fluorescence-activated cell sorting analysis ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). We strengthened the link between EZH2 expression and KLF2 repression by establishing a U2OS cell line stably transfected with a short hairpin RNA (shRNA) against EZH2 ([Figure 1c](#fig1){ref-type="fig"} and [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). EZH2--shRNA (Origene, Rockville, MD, USA) transfection was accomplished by electroporation and cells were selected with puromycin (Calbiochem, Darmstadt, Germany). The stable inhibition of EZH2 expression also led to a marked increase in KLF2 mRNA ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}) and protein levels ([Figure 1c](#fig1){ref-type="fig"}).

The observed inverse association between EZH2 and KLF2 levels might be mediated by a direct effect of EZH2 on the KLF2 promoter or by secondary mechanisms. Thus, we performed quantitative chromatin immunoprecipitation (qChIP) for the minimal promoter of KLF2 using antibodies against EZH2, the trimethylated H3K27 mark (3meH3K27) established by the enzyme and phosphorylated serine 2 of RNA polymerase (RNAP-S2, a marker of active transcription). A nonspecific IgG antibody was used as a technical negative control, the EZH2-target gene *ADRB2* ([@bib24]) was used as a positive control and the GAPDH locus was used as a negative control. Measurements were made in triplicate and the polymerase chain reactions (PCRs) were done using the Prism 7900 HT Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA). The qChIP analyses demonstrated an enriched presence of EZH2 and 3meH3K27 in the KLF2 promoter for the described cancer cell lines ([Figure 2A](#fig2){ref-type="fig"}). Conversely, RNAP-S2 was depleted at this locus ([Figure 2A](#fig2){ref-type="fig"}). The EZH2 RNAi experiments reduced EZH2 occupancy and 3meH3K27 presence and induced the recruitment of RNAP-S2 for the KLF2 promoter ([Figure 2A](#fig2){ref-type="fig"}). These results for the 5′-end of the *KLF2* gene were similar to those obtained from the qChIP data of the well-known EZH2-target gene *ADRB2* ([@bib24]) ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). The U2OS cells that were stably depleted at EZH2 by shRNA reproduced this qChIP pattern ([Figure 2B](#fig2){ref-type="fig"}). In these cells, evidence for the role of EZH2 in directly repressing KLF2 was reinforced by the results of luciferase assays ([Figure 2C](#fig2){ref-type="fig"}). Finally, the link between EZH2 binding to the 5′-end of the KLF2 and its corresponding silencing was corroborated by the use of the small molecule 3-Deazaneplanocin A (DZNep), which depletes the cellular levels of Polycomb-repressive complex 2 components, including EZH2 ([@bib18]). Upon DZNep treatment, a marked increase in KLF2 expression was observed in U2OS cells ([Figure 2D](#fig2){ref-type="fig"}). The DZNep-mediated enhancement of KLF2 expression was associated with the depletion of EZH2 occupancy and 3meH3K27 levels and an enrichment of RNAP-S2 in the KLF2 promoter determined by qChIP ([Figure 2D](#fig2){ref-type="fig"}). From the DNA methylation standpoint, the KLF 5′-end region contains a canonical CpG island that remained unmethylated under all the experimental conditions described ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}).

Once we had determined that KLF2 was a direct target of transcriptional repression by EZH2 in cancer cells, we sought to understand the molecular and cellular contribution of KLF2 silencing to the transformed phenotype. To this end we constructed a FLAG-tagged KLF2 expression vector using the pCMV-Tag2B vector (Stratagene, Santa Clara, CA, USA) and transfected it by electroporation to U2OS cells. Transfected cells were selected by adding G418 (Calbiochem). Upon KLF2 transfection, we observed enhanced Annexin V expression relative to empty vector-transfected cells ([Figure 3A](#fig3){ref-type="fig"}). The pro-apoptotic effect mediated by KLF2 transfection was also associated with an increase in the expression levels of the cell cycle-inhibiting genes p15/CDKN2B and p21/CDKN1A, as determined by qRT--PCR ([Figure 3B](#fig3){ref-type="fig"}) and western blot ([Figure 3B](#fig3){ref-type="fig"}). These two latter genes could be direct or indirect targets of the transcription factor KLF2. The two possibilities can be discriminated by the chromatin immunoprecipitation assay. The qChIP analyses demonstrated an enriched presence of KLF2 (using a FLAG-M2 antibody) in the 5′-end CpG islands of p15/CDKN2B and p21/CDKN1A in the transfected U2OS cells ([Figure 3C](#fig3){ref-type="fig"}). The KLF2 occupancy at these promoters also occurred with an enrichment of active transcription marks, such as RNAP-S2 occupancy and the trimethylation of lysine 4 of histone H3 ([Figure 3C](#fig3){ref-type="fig"}).

From the point of view of cellular growth, KLF2 also had the expected features of a tumor suppressor gene. KLF2-transfected U2OS cells showed a marked reduction of proliferation determined by both the MTT ([Figure 3D](#fig3){ref-type="fig"}) and colony-formation ([Figure 3D](#fig3){ref-type="fig"}) assays. Conversely, stable depletion of KLF2 by shRNA in the non-transformed MRC5 fibroblast cells increased cell viability as assessed by the MTT assay ([Figure 3E](#fig3){ref-type="fig"}). We also wished to investigate the contribution of KLF2 repression to the overall tumorigenic phenotype conferred by EZH2. To do this, we first depleted EZH2 by RNAi in U2OS cells ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}) and observed that the induced diminished levels of EZH2 were associated with a lower level of cell proliferation, as determined by the MTT assay ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). This finding was consistent with those of previous reports ([@bib20]; [@bib4]). As also described above, EZH2--RNAi caused KLF2 upregulation ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). We proceeded to knock down KLF2 by RNAi in the EZH2-depleted cells to investigate whether the loss of KLF2 was able to 'rescue\' partially the oncogenic phenotype mediated by EZH2. We observed that the double RNAi against EZH2 and KLF2 (EZH2-/KLF2- cells) gave rise to cells with a higher proliferation rate than those with single EZH2 depletion ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). Thus, KLF2 transcriptional silencing is an important step in the proliferation pathways mediated by the EZH2 oncogene.

We extended the study of the KLF2 growth-inhibitory role to *in vivo* mouse models. Athymic (nu/nu) mice, aged 4--5 weeks, were used for tumor xenograft models. The experimental design was approved by the Bellvitge Biomedical Research Institute Ethical Board. The mice were killed 30 days after injection and tumors were excised and weighed, while the mean volume of tumors±standard error of the mean (s.e.m.) was also calculated. The subcutaneous injection of 3 × 10^6^ U2OS cells in nude mice demonstrated that KLF2-transfected cells (U2OS-pCMV-KLF2) developed significantly smaller tumors than empty vector-transfected U2OS cells (Student\'s *t*-test, *P*=0.028) ([Figure 4a](#fig4){ref-type="fig"}). The characterization of the spreading potential was developed by tail-vein injection in the mice of 1 × 10^6^ U2OS cells suspended in 0.2 ml phosphate-buffered saline, and the survival rate at 40 days was analyzed by the Kaplan--Meier method. U2OS-pCMV-KLF2-transfected cells had a significantly lower mortality rate than U2OS empty vector-transfected cells (*P*\<0.001) ([Figure 4b](#fig4){ref-type="fig"}). Depletion of EZH2 by shRNA had a similar effect in the reduction of mortality ([Figure 4b](#fig4){ref-type="fig"}).

Finally, we decided to translate part of these findings to the context of human primary tumors. We assessed EZH2 and KLF2 expression by immunostaining in clinical tumor samples using a cancer tissue microarray that includes prostate and breast cancer tissue samples with clinical data (SuperBioChips Laboratories, Seoul, Korea). [Supplementary Table 1](#sup1){ref-type="supplementary-material"} summarizes the EZH2/KLF2 expression and clinical data from each individual prostate (*n*=40) and breast (*n*=15) cancer case. We observed that KLF2 expression was inversely associated with EZH2 expression in prostate (Pearson\'s correlation coefficient *r*^2^=0.32, *P*\<0.05) and breast (Pearson\'s correlation coefficient *r*^2^=0.57, *P*\<0.05) tumors ([Figure 4c](#fig4){ref-type="fig"}). Most importantly, the comparison of the expression data against the clinicopathological values showed that the combination of low KLF2 and high EZH2 expression was associated with shorter overall survival in breast and prostate cancer (Kaplan--Meier analysis, *P*=0.013 and 0.062, respectively) ([Figure 4d](#fig4){ref-type="fig"}).

Overall, our data indicate that KLF2 undergoes transcriptional silencing in human tumorigenesis by the direct repression of an oncogenic Polycomb protein, the histone methyltransferase EZH2. The EZH2-mediated inactivation of KLF2 blocks the tumor-suppressor features of the KLF2 protein, such as its pro-apoptotic and cell cycle-inhibitory capacities, mediated by p15/CDKN2B and p21/CDKN1A, and its growth-inhibitory features demonstrated in cellular and animal models. Most importantly, the EZH2-mediated loss of KLF2 predicts a poor outcome in human malignancies.

We thank O Domínguez for help with the microarray procedures and analysis, F Setien for technical assistance and Miki Kojiya for the flow cytometry analysis. This work was supported by Grants SAF2007-00027-65134, Consolider CSD2006-49, and Lilly Foundation and Dr Josef Steiner Cancer Research Foundation to ME, and the Intramural Research Program of the NIH, National Cancer Institute and Center for Cancer Research to VEM. HT is supported by the Uehara Memorial Foundation and Pancreas Research Foundation of Japan. ME is an ICREA Research Professor.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies the paper on the Oncogene website (http://www.nature.com/onc)

The authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

###### 

Click here for additional data file.

![EZH2 depletion leads to increased KLF2 mRNA and protein levels. Expression of KLF2 and EZH2 determined by qRT--PCR (**a**) and (**b**) immunoblot in five cancer cell lines (U2OS, MDA-MB-231, MCF-7, PC3 and LNCaP cells) following transfection with oligo-type short interfering RNA (siRNA) against EZH2 or scrambled siRNA for 72 h as a transient model. (**c**) Immunoblot of EZH2 and KLF2 in stable EZH2 knockdown clones. U2OS cells are transfected with shRNA constructs targeting EZH2 or control vector and undergo selection with puromycin. *P*-values obtained from Student\'s *t*-test.](onc2011387f1){#fig1}

![EZH2 direct binding to the KLF2 promoter mediates the transcriptional repression effect. (**A**) ChIP\--qPCR of EZH2 occupancy and H3K27-3me marks in the *KLF2* promoter in five cancer cell lines treated with EZH2 siRNA (72 h) or scrambled siRNA. Treatment with siRNA against EZH2 prevents EZH2 occupancy and the presence of the H3K27-3me mark, while enhanced RNAP binding is observed in the *KLF2* promoter. ChIP was performed using polyclonal antibodies raised in rabbit against EZH2 (pAb-039-050, Diagenode, Liège, Belgium), RNAP-S2 (ab5095, Abcam, Cambridge, UK) and H3K27me3 (pAB-069-05, Diagenode), with rabbit IgG as a control (ab37415, Abcam, ChIP grade). The primers used for the ChIP\--qPCR analysis of the KLF2 promoter were 5′-GAGACTCCAGACTTCCCATCC-3′ (sense) and 5′-CAGAGACTCTCAGGGGAGCAC-3′ (antisense). (**B**) qChIP for EZH2 occupancy and H3K27-3me presence for the *KLF2* promoter in stable EZH2 knockdown clones (U2OS-shEZH2). (**C**) *KLF2* promoter activities are analyzed by luciferase reporter assay in stable EZH2 knockdown clones. In each experiment, firefly luciferase activities are normalized against those of Renilla. *n*=3, mean±s.e.m. (error bars). We used a pGL3 Luciferase Reporter Vector (Promega, Madison, WI, USA) for the KLF2 promoter encompassing *Nhe*I/*Hin*d III sites (from −916 to +129 bp). (**D**) Upregulation of *KLF2* transcript (a) and protein (b) upon treatment with 5 μ DZNep for 72 h. (c) qChIP analysis shows how the treatment with DZNep decreased EZH2 occupancy and the H3K27-3me mark in the KLF2 promoter, while it enhanced RNAP-S2 occupancy. *P*-values obtained from Student\'s *t*-test.](onc2011387f2){#fig2}

![KLF2 induces apoptosis, directly activates the cell cycle-inhibiting genes p15/CDKN2B and p21/CDKN1A and inhibits cell proliferation. (**A**) Enhanced Annexin V expression relative to empty vector-transfected cells upon KLF2 transfection. The right panels are the original red color/FL-4 (annexin-Cy5) histograms that show how KFL2 transfection induces apoptosis, demonstrated by the increase in the number of cells that incorporate higher amounts of annexin V. (**B**) U2OS cells transfected with a FLAG-tagged KLF2 (pCMV-Tag2B-KLF2) expression vector show increased expression of p15^Ink4b^ and p21^CDKN1A^, determined by qRT--PCR (a) and western blot (b). (**C**) The ectopically expressed KLF2 (FLAG-tagged KLF2) occupied the p15^Ink4b^ and p21^CDKN1A^ promoters in association with a gain of RNAP-S2 occupancy and the H3-K4 trimethylation mark determined by qChIP. (**D**) MTT (left) and colony formation (right) assays reveal that stable KLF2-expressing U2OS cells grow more slowly than cells transfected with control vector. (**E**) Enhanced proliferation of normal MRC5 fibroblasts after transfection of shRNA against KLF2 in comparison with scrambled shRNA. *P*-values obtained from Student\'s *t*-test.](onc2011387f3){#fig3}

![KLF2 as a tumor suppressor in mouse models and its effect on human tumors. (**a**) Effect of sh-EZH2 knockdown (left) or KLF2 transfection (right) on the growth of U2OS cells inoculated into nude mice. Tumor volume was monitored over time, and the tumor was excised and weighed after 24 days. EZH2 depletion or KLF2 overexpression cause a reduction in tumor volume and weight. (**b**) Significantly lower mortality following tail-vein injection in the mice of 1 × 10^6^ U2OS cells was observed in U2OS-pCMV-KLF2 or U2OS-shEZH2 cells in comparison with the empty vector-transfected cells (*P*\<0.001) (**c**) EZH2 and KLF2 expression in clinical cancer samples determined by immunostaining in prostate and breast cancer tissue microarrays. KLF2 expression was inversely associated with EZH2 expression in prostate (Pearson\'s correlation coefficient *r*^2^=0.32, *P*\<0.05*, n*=40) and breast (Pearson\'s correlation coefficient *r*^2^=0.57, *P*\<0.05, *n*=15) cancer. (**d**) The high expression of EZH2 associated with the low expression of KLF2 predicts overall shorter survival in breast and prostate cancer (Kaplan--Meier analysis, *P*=0.013 and *P*=0.062, respectively).](onc2011387f4){#fig4}
